Increased gallbladder emptying and reduced GLP‐1 response in pregnancy with and without gestational diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 697, doi. 10.1111/dom.16064
- By:
- Publication type:
- Article
Works by Andersen, Emilie S.
Results: 6
1
2
Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 201, doi. 10.1111/dom.15306
- By:
- Publication type:
- Article
3
Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 1937, doi. 10.1111/dom.13321
- By:
- Publication type:
- Article
4
Do we know the true mechanism of action of the DPP-4 inhibitors?
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 34, doi. 10.1111/dom.13018
- By:
- Publication type:
- Article
5
Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference.
- Published in:
- 2017
- By:
- Publication type:
- journal article
6
10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-10-OR
- By:
- Publication type:
- Article